Two randomized studies published Tuesday in JAMA Internal Medicine found that no advantages are gained in the arthritis drug to treat Covid-19, while an observational study also published in the journal found that this can reduce hospital mortality rates, while researchers are trying to identify an effective coronavirus. treatment with emerging cases.
One of the randomized studies, the popular gold of clinical trials, found that out of 123 patients in Italy, 17 out of 60 who won tocilizumab and 17 out of 63 who received popular care had worsened after 14 days, and two other people receiving the drug had died opposite death in the group.
The other study, founded in France, followed 130 patients with Covid-19 and pneumonia who required oxygen supplements but were not admitted to the intensive care unit, and found that the threat of ventilation and death could possibly have been reduced until the 14th day of treatment. however, daily mortality remained the same.
Nearly 4,000 patients in the United States were interviewed in the observational study, and 11% received tocilizumab within the first two days of ICU admission.
Noting that patients treated with the drug had a lower median age (58 versus 63), the researchers found that 28. 9% of patients taking tocilizumab died compared to 40. 6% who did not.
The observational study noted in its findings that “the effects would possibly be vulnerable to unfounded confusion, and additional studies of randomized clinical trials are needed”.
There is no cure for Covid-19 and a widely distributed vaccine is still in months. A recent large-scale randomized trial of 4 medicines – remdesivir, hydroxychloroquine, lopinavir/ritonavir and interferon – coordinated through the World Health Organization has been described as “not promising” in terms of mortality, onset of ventilation and duration of hospitalization. Remdesivir is the only express drug with emergency use authorization from the Food and Drug Administration. The effects came shortly after a study published in the New England Journal of Medicine that found that remdesivir shortened the recovery time of adults hospitalized by Covid-19, hydroxychloroquine, an antimalarial drug, has remained useless in studies. He was also harassed by politics, with President Trump selling the drug during the pandemic, but did not later obtain it by hiring Covid-19.
Promising early studies of tocilizumab required more randomized data, whether studies published in JAMA join a disappointing first Hoffmann-La Roche Phase 3 trial. Among arthritis medications, Eli Lilly’s baricitinib has been shown to be effective in a study sponsored through the National Institutes. The company reported that a mixture of baricitinib and remdesivir reduced hospitalization remains and higher survival rates in patients with severe symptoms. There are 40. 6 million cases overall of coronavirus and 1. 1 million reported deaths. with America at the forefront.
Full policy and updates on the coronavirus
I have the latest news and I also report on the video game industry. I have already written for sites like IGN, Polygon, Red Bull eSports, Kill Screen, Playboy and PC Gamer.
I can see the latest news and also report on the video game industry. I have already written for sites like IGN, Polygon, Red Bull eSports, Kill Screen, Playboy and PC Gamer. I also controlled a YouTube game channel under the so-called strummerdood. I received a bachelor’s degree in journalism from Rowan University and did an internship at Philadelphia Magazine. You can follow me on Twitter @mattryanperez.